Losartan Potassium Tablet
Product Images NDC 70010-742

8 FDA label images from Granules Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70010-742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan-structure-jpg (Losartan Structure Jpg)

Losartan-structure-jpg (Losartan Structure Jpg)
Chemical structure diagram of Losartan Potassium, showing its molecular arrangement including rings, chlorine atom, potassium ion, and other chemical groups.*
FDA Label Image

Fig-1 (Fig 1)

Fig-1 (Fig 1)
A line graph comparing the percentage of patients with primary endpoint events over study months for Atenolol and Losartan Potassium. The x-axis represents the study month up to 66 months, and the y-axis shows the percentage of patients with primary endpoint events up to 16%. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021.*
FDA Label Image

Fig-2 (Fig 2)

Fig-2 (Fig 2)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between Atenolol (dashed line) and Losartan potassium (solid line). The graph shows a lower percentage for Losartan potassium, with an adjusted risk reduction of 25% (p=0.001).*
FDA Label Image

Fig-3 (Fig 3)

Fig-3 (Fig 3)
A forest plot comparing Losartan Potassium and Atenolol across various patient subgroups, including overall results, age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease. The plot shows hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) outcomes, visually indicating which treatment is favored in each category.*
FDA Label Image

Losartan-figure4-jpg (Losartan Figure4 Jpg)

Losartan-figure4-jpg (Losartan Figure4 Jpg)
A line graph showing the percentage of patients with an event over 48 months, comparing Losartan potassium to placebo. The graph indicates a 16.1% risk reduction with Losartan potassium, with a p-value of 0.022. The solid line represents Losartan potassium and the dotted line represents placebo.*
FDA Label Image

100-mg-30s (100 mg 30s)

100-mg-30s (100 mg 30s)
Losartan Potassium Tablets, USP 100 mg oral tablets label shows a package of 30 tablets. It is manufactured by Granules India Limited in India and distributed by Granules Pharmaceuticals Inc., Chantilly, VA. The label includes storage instructions, dosage reference, and a website for patient information.*
FDA Label Image

62207-742-03 (62207 742 03)

62207-742-03 (62207 742 03)
Losartan Potassium Tablets USP 50 mg label showing product strength, quantity of 30 tablets, and Rx only designation. The label includes storage instructions, manufacturer Granules India Limited in Hyderabad, India, and distributor Granules Pharmaceuticals Inc. in Chantilly, VA. Barcodes and a patient information notice for pharmacists are also visible.*
FDA Label Image

70010-741-03 (70010 741 03)

70010-741-03 (70010 741 03)
Losartan Potassium Tablets USP 25 mg oral tablets packaging label showing a quantity of 30 tablets. The label includes storage instructions, manufacturer Granules India Limited (Hyderabad, India), and distributor Granules Pharmaceuticals Inc. (Chantilly, VA). It also features a barcode and directs to patient information leaflet online.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.